StreetInsider.com News Articles

Alector to Participate in Upcoming Healthcare Conferences

Thu, 03 Sep 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference 2026 (New York, New York)
Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat

Morgan Stanley 24th Annual Global Healthcare Conference (New York, New York)
Tuesday, September 15, 2026, at 7:00 a.m. ET, fireside chat

A live webcast of each fireside chat will be available on the "Events &

Alector to Participate in Upcoming Healthcare Conferences

Thu, 03 Sep 2026 16:05:00 -0400

Cantor Global Healthcare Conference 2026 (New York, New York)
Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat

Morgan Stanley 24th Annual Global Healthcare Conference (New York, New York)
Tuesday, September 15, 2026, at 7:00 a.m. ET, fireside chat

A live webcast of each fireside chat will be available on the "Events &

Form 4 Alector, Inc. For: Aug 19 Filed by: Rosenthal Arnon

Fri, 21 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962632.html

Form 4 Alector, Inc. For: Aug 19 Filed by: Rosenthal Arnon

Fri, 21 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962632.html

Alector Inc. (ALEC) Tops Q2 EPS by 2c

Thu, 06 Aug 2026 18:06:58 -0400

Alector Inc. (NASDAQ: ALEC) reported Q2 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.32 million versus the consensus estimate of $2.12 million.

For earnings history and earnings-related data on Alector Inc. (ALEC) click here.

Form 10-Q Alector, Inc. For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884266.html

Form 10-Q Alector, Inc. For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884266.html

Form 8-K Alector, Inc. For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884023.html

Form 8-K Alector, Inc. For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884023.html

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD).

Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)).

$172.8 million in cash, cash equivalents and investments provide runway at least through 2027

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)).

$172.8 million in cash, cash equivalents and investments provide runway at least through 2027

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating

Form 4 Alector, Inc. For: Jul 09 Filed by: Wong-Sarad Grace

Thu, 09 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260709/26753226.html

Form 4 Alector, Inc. For: Jul 09 Filed by: Wong-Sarad Grace

Thu, 09 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260709/26753226.html

GSK terminates collaboration with Alector after trial failures

Wed, 08 Jul 2026 16:13:44 -0400

Alector Inc. (NASDAQ: ALEC) disclosed that GlaxoSmithKline unit Glaxo Wellcome UK Limited has moved to terminate its collaboration and license agreement with the company, following the failure of two clinical trials.

GSK provided written notice of termination on July 6, 2026. Under the agreement's terms, the termination becomes effective 180 days from that notice, on January 2, 2027.

The termination follows two clinical setbacks. In October 2025, Alector's Phase 3 INFRONT-3 trial evaluating latozinemab in patients with frontotemporal dementia due to a progranulin gene mutation failed to meet its co-primary clinical endpoint. In April 2026, the company discontinued its Phase 2 PROGRESS-AD

GSK terminates collaboration with Alector after trial failures

Wed, 08 Jul 2026 16:13:44 -0400

GSK provided written notice of termination on July 6, 2026. Under the agreement's terms, the termination becomes effective 180 days from that notice, on January 2, 2027.

Form 8-K Alector, Inc. For: Jul 06

Wed, 08 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26747589.html

Form 8-K Alector, Inc. For: Jul 06

Wed, 08 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26747589.html

Form 4 Alector, Inc. For: Jun 17 Filed by: Hammond Paula